大成生化科技(00809.HK)盈警:預期中期將取得重大淨虧損
格隆匯6月30日丨大成生化科技(00809.HK)發佈公吿,於截至2022年5月31日止五個月錄得淨虧損約6.47億港元。因此,與上年同期約5.06億港元淨利潤相比,集團於截至2022年6月30日止六個月預期將錄得重大淨虧損。
集團於該期間錄得淨虧損,主要是由於其他收入較2021年同期減少所致。謹此提述公司及大成糖業控股有限公司於2021年3月26日的聯合公吿,內容有關長春潤德投資集團有限公司與集團、大成糖業集團及長春大金倉玉米收儲有限公司各自訂立的債務回購協議。於債務回購協議完成後,集團(包括大成糖業集團)於截至2021年6月30日止六個月錄得一次性的債務重組收益約13.25億港元,而該期間並未錄得有關收益。因此,預期集團於該期間的其他收入將大幅下降。
由於上海新型冠狀病毒肺炎疫情受控,且封鎖措施自2022年五月底起分階段解除,集團自2022年六月起已逐步恢復集團部分上海生產設施的運作。集團將密切監察新型冠狀病毒肺炎疫情發展及中國政府所採取的相關措施,以確定集團上海生產設施全面恢復運作的適當時機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.